Hemostemix Asia

Hemostemix is a clinical-stage biotechnology company focused on developing and commercializing autologous cell therapies for the treatment of ischemic diseases. The company's flagship product, ACP-01, consists of synergistic populations of angiogenic cell precursors derived from a patient's own blood, designed to promote new blood vessel formation and restore blood flow to ischemic tissues. Hemostemix is primarily targeting critical limb ischemia (CLI), a severe form of peripheral arterial disease, and has demonstrated promising results in Phase 2 clinical trials. The company utilizes its proprietary Syzix II automated manufacturing platform to produce standardized, high-quality cell therapy products at scale.